Purpose
This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients with ErbB1-expressing and/or ErbB2-overexpressing advanced-stage refractory solid tumors.

Patients and Methods
Heavily pretreated patients with ErbB1-expressing and/or ErbB2-overexpressing metastatic cancers were randomly assigned to one of five dose cohorts of lapatinib administered once daily. Pharmacokinetic samples were obtained on days 1 and 20. Clinical response was assessed every 8 weeks.

Results
Sixty-seven patients with metastatic solid tumors were treated with lapatinib. The most frequently reported drug-related adverse events were diarrhea (42%) and rash (31%). No grade 4 drug-related adverse events were reported. Five grade 3 drug-related toxicities (gastrointestinal events and rash) were experienced by four patients. Drug-related interstitial pneumonitis or cardiac dysfunction associated with other ErbB-targeted therapies was not reported. Four patients with trastuzumab-resistant metastatic breast cancer—two of whom were classified as having inflammatory breast cancer—had partial responses (PRs). Twenty-four patients with various other carcinomas experienced stable disease, of whom 10 received lapatinib for ≥ 6 months. The relationships between lapatinib dose or serum concentration and clinical response could not be adequately characterized due to the limited response data. The incidence of diarrhea increased with increasing dose, whereas the incidence of rash was not related to dose.

Conclusion
Lapatinib was well tolerated at doses ranging from 500 to 1,600 mg once daily. Clinical activity was observed in heavily pretreated patients with ErbB1-expressing and/or ErbB2-overexpressing metastatic cancers, including four PRs in patients with trastuzumab-resistant breast cancers and prolonged stable disease in 10 patients.

INTRODUCTION
In humans, the ErbB family of transmembrane tyrosine kinase receptors consists of four members: ErbB1 (epidermal growth factor receptor [EGFR]), ErbB2, ErbB3, and ErbB4.1,2 Expression of ErbB1 and/or overexpression of ErbB2 occur to varying degrees in epithelial malignancies, where they promote tumor cell growth/survival, and in certain tumors predict for a poor clinical outcome.3-6 Upon ligand binding, ErbB receptors form hetero- or homodimers.
resulting in the autophosphorylation of specific tyrosine residues within the conserved catalytic kinase domains of ErbB receptors.1,2 These phosphorylated tyrosine residues serve as docking sites for Src-homology 2 and phosphotyrosine-binding domain—containing proteins that link activated ErbB receptors to downstream cell proliferation (mitogen-activated protein kinase [MAPK]) and survival (phosphotyrosinyl-kinase [PI3K]) pathways.1,2,7-12 The established role of ErbB1 and ErbB2 in promoting the growth and survival of various types of solid tumors makes them attractive therapeutic targets. Monoclonal antibodies such as cetuximab and trastuzumab targeting ErbB1 and ErbB2, respectively, as well as small-molecule tyrosine kinase inhibitors of ErbB1 (eg, gefitinib and erlotinib) have been shown to inhibit proliferation of ErbB1- or ErbB2-expressing cancer cells.13-17 Moreover, clinical studies have demonstrated the activity of these ErbB-targeted agents in patients with advanced stage malignancies.18-22

Lapatinib (GW572016) is an orally active small molecule that reversibly inhibits ErbB1 and ErbB2 tyrosine kinases, leading to inhibition of MAPK and PI3K signaling in ErbB1-expressing and ErbB2-overexpressing tumor cell lines and xenografts.23,24 Lapatinib-treated tumor cells undergo apoptosis or growth arrest depending upon the cell type.23,24 ErbB2, the only member of the ErbB family without an exogenous ligand, is the preferred heterodimer partner for other ErbB receptors where it amplifies the biologic signal.1,7 Since ErbB2-containing heterodimers exert potent growth and survival effects, simultaneous inhibition of ErbB2 and ErbB1 is an appealing therapeutic strategy.

In phase I studies in healthy volunteers, lapatinib was well tolerated at repeat doses up to the highest dose administered (175 mg/d).25 In the first phase I dose escalation study in cancer patients (EGF10003), lapatinib was well tolerated at doses up to the highest dose administered (1,800 mg once daily) with mild and transient diarrhea, nausea, rash, fatigue, anorexia, and vomiting as the predominant toxicities.26 Clinical activity was observed at doses of 650 mg/day and higher.26

Pharmacokinetic data from these studies indicated that serum lapatinib concentrations peak 4 hours after dosing, increase with increasing dose, accumulate approximately two-fold with daily dosing, and achieve steady state in 6 to 7 days, suggesting an effective half-life of 24 hours.

This study (EGF10004) was designed to (1) assess the safety and tolerability of lapatinib after multiple dosing; (2) assess the pharmacokinetics of lapatinib; (3) evaluate the biologic effects of lapatinib in serial tumor biopsies; (4) determine a biologically active dose range for lapatinib; and (5) assess the clinical activity of lapatinib. The biologic effects of lapatinib on signaling pathways in tumor tissue obtained from a subset of 33 patients participating in this study who had sequential biopsies were recently reported.27 The safety/tolerability, pharmacokinetics, and clinical activity of lapatinib are reported here.

## PATIENTS AND METHODS

### Eligibility Criteria

Patients enrolled in this study were males or females age 18 years or older with a histologically-confirmed diagnosis of cancer; had an archived or fresh biopsy that demonstrated expression of ErbB1 (positive by immunohistochemistry [IHC]) and/or overexpression of ErbB2 (2+ or 3+ by IHC) or that displayed gene amplification of ErbB2 by fluorescence in situ hybridization; had a Karnofsky performance status ≥ 70%; had a life expectancy of at least 12 weeks; had a hemoglobin concentration ≥ 9 g/dL (5 mmol/L), an absolute granulocyte count ≥ 1,500/mm3 (1.5 × 10⁹/L), a platelet count ≥ 100,000/mm³ (100 × 10⁹/L); and were able to swallow and retain oral medication. Patients were excluded from the study if they were pregnant or lactating females; had malabsorption syndrome; received any chemotherapy within the previous 4 weeks or treatment with nitrosourea or mitomycin within the previous 6 weeks; received biologic, hormonal, or radiation therapy within the previous 4 weeks; were taking steroids; had a total bilirubin > 2 mg/dL; had AST or ALT > 3 × the upper limit of normal; had a class III or IV heart failure as defined by the New York Heart Association functional classification system; or had a left ventricular ejection fraction (LVEF) < 40%. All patients provided a signed informed consent.

The study protocol was approved by institutional review boards at the following institutions: TriStar Nashville Market, Nashville, TN; Duke University Health System, Durham; University of North Carolina School of Medicine, Chapel Hill, NC; and University Hospitals of Cleveland, Cleveland, OH. The study was conducted in accordance with the 1996 version of the Declaration of Helsinki.

### Safety Assessments

Patients underwent a physical examination, vital sign measurements, Karnofsky performance status, basic ophthalmologic examination, 12-lead ECG, multigated angiogram (MUGA) scan, hematology, clinical chemistry, and urinalysis performed within 14 days before the first dose of study drug. Physical examination, vital signs, and safety laboratory evaluations were repeated on days 1 and 20. Adverse events (AEs) were graded using the National Cancer Institute Common Toxicity Criteria version 2.0. Patients who continued therapy after Day 21 had safety assessments performed every 4 weeks. ECG and MUGA scans were repeated every 8 weeks during treatment. A poststudy evaluation was required 28 days after the last dose of lapatinib was administered.

### Study Treatments

This was a randomized, parallel-group, repeated dosing study in patients with solid tumors. Lapatinib (GlaxoSmithKline, Research Triangle Park, NC) was supplied as 100-mg and 250-mg tablets for daily oral administration. Sixty-seven patients were randomly assigned to receive one of five oral doses of lapatinib administered daily for 21 days. The doses administered were chosen on the basis of safety, tolerability, and pharmacokinetic data from prior healthy volunteer28 and cancer patient29 studies, and included 500, 650, 900, 1,200, and 1,600 mg of lapatinib. The protocol allowed investigator discretion in making upward dose adjustments in patients who were...
assessed as having progressive disease. An amendment was written, but not fully implemented, that included two additional dose groups of 1,000 and 2,000 mg of lapatinib administered daily. After completing the initial 21-day portion of the study, patients continued on once-daily lapatinib therapy until disease progression, treatment-emergent toxicities, or withdrawal of consent.

**Pharmacokinetic Assessments**

Blood samples were taken for determination of serum lapatinib concentration on days 1 and 20 before dosing, and at 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing. Serum was separated and stored at −20°C until analysis. Concentrations of lapatinib were measured by liquid chromatography tandem mass spectrometry with parallel online turbulent flow extraction and positive ion selected reaction monitoring, as previously described.28 The calibration range of the lapatinib assay was 1 to 1,000 ng/mL. Interassay precision was within 12%, and interassay accuracy was within 8% of nominal. Pharmacokinetic analyses were performed using WinNonlin 3.2 software (Pharsight, Mountain View, CA). Standard noncompartmental methods were used to calculate area under the serum concentration versus time curve within the dosing interval (AUC), peak serum concentration (Cmax), the time at which Cmax occurred (tmax) on days 1 and 20, and steady-state trough concentration (Cmin) on day 20.

**Evaluation of Clinical Activity**

Disease status was assessed predose, after 8 weeks of therapy, and every 8 weeks thereafter until withdrawal from the study using the Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines.29 Patients who did not have lesions that were assessable by RECIST (eg, dermatologic changes consistent with inflammatory breast cancer) were evaluated by clinical assessment.

**RESULTS**

**Patient Characteristics**

Sixty-seven patients were enrolled at four sites in the United States between March 2002 and May 2003. Patients were randomly assigned to one of five daily dose cohorts (500 mg [n = 13], 650 mg [n = 15], 900 mg [n = 11], 1,200 mg [n = 12], and 1,600 mg [n = 13]), with the later addition of a cohort at 1,000 mg daily (n = 3). Patient characteristics are shown in Table 1. The study population included patients with a variety of solid tumors, with breast cancer being the most common (n = 30). The patient population was heavily pretreated, with 66 patients (99%) having received previous chemotherapy. These patients received a median of five prior therapies with a range of one to 14.

**Safety and Tolerability**

Forty-four (66%) of 67 patients experienced drug-related AEs. The most frequently reported drug-related AEs were diarrhea (42%) and rash (31%) (Table 2). Other drug-related AEs included nausea (13%) and fatigue (10%); all remaining drug-related AEs occurred with an incidence of 5% or less. Most drug-related AEs (135 of 140) were mild in intensity (grade 1 or 2). Five grade 3 AEs experienced by four patients were considered to be drug-related: one patient had grade 3 abdominal pain at the 650-mg dose level, one patient had grade 3 rash and grade 3 diarrhea at the 1,000-mg dose level that required a dose reduction to 500 mg; one patient had grade 3 diarrhea at the 1,200-mg dose level that required temporary interruption of lapatinib (the patient continued to experience grade 2 diarrhea at a reduced dose of 650 mg and was subsequently withdrawn); one patient who initially received 900 mg and subsequently received 1,600 mg lapatinib was withdrawn due to grade 3 gastrointestinal reflux disease. The gastrointestinal reflux was believed by the investigator to be related to the large pill burden.

### Table 1. Patient Characteristics by Lapatinib Dose Cohort

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>500 mg</th>
<th>650 mg</th>
<th>900 mg</th>
<th>1,000 mg</th>
<th>1,200 mg</th>
<th>1,600 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Age, years</td>
<td>Median</td>
<td>Range</td>
<td>Median</td>
<td>Range</td>
<td>Median</td>
<td>Range</td>
</tr>
<tr>
<td>Prior treatments</td>
<td>Median</td>
<td>Range</td>
<td>Median</td>
<td>Range</td>
<td>Median</td>
<td>Range</td>
</tr>
<tr>
<td>Disease site</td>
<td>Breast</td>
<td>6 6 5 3 6 4</td>
<td>6 7 5 6 4 5</td>
<td>2-10</td>
<td>1-11</td>
<td>1-13</td>
</tr>
<tr>
<td></td>
<td>AU</td>
<td>1 1 2 0 0 1</td>
<td>1 1 2 0 0 1</td>
<td>1 1 2 0 0 1</td>
<td>1 1 2 0 0 1</td>
<td>1 1 2 0 0 1</td>
</tr>
<tr>
<td></td>
<td>CRC</td>
<td>2 2 1 0 1 1</td>
<td>2 2 1 0 1 1</td>
<td>1 1 2 0 0 1</td>
<td>2 2 1 0 1 1</td>
<td>2 2 1 0 1 1</td>
</tr>
<tr>
<td></td>
<td>H&amp;N</td>
<td>0 1 0 0 2 2</td>
<td>0 1 0 0 2 2</td>
<td>0 1 0 0 2 2</td>
<td>0 1 0 0 2 2</td>
<td>0 1 0 0 2 2</td>
</tr>
<tr>
<td></td>
<td>Ovarian</td>
<td>1 1 1 0 0 1</td>
<td>1 1 1 0 0 1</td>
<td>1 1 1 0 0 1</td>
<td>1 1 1 0 0 1</td>
<td>1 1 1 0 0 1</td>
</tr>
<tr>
<td></td>
<td>Lung</td>
<td>1 2 2 0 2 3</td>
<td>1 2 2 0 2 3</td>
<td>1 2 2 0 2 3</td>
<td>1 2 2 0 2 3</td>
<td>1 2 2 0 2 3</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>2 0 0 0 1 1</td>
<td>2 0 0 0 1 1</td>
<td>2 0 0 0 1 1</td>
<td>2 0 0 0 1 1</td>
<td>2 0 0 0 1 1</td>
</tr>
</tbody>
</table>

**Abbreviations:** AU, adenocarcinoma of unknown primary origin; CRC, colorectal cancer; H&N, head and neck carcinoma.

### Table 2. No. of Patients with Drug-Related Adverse Events That Occurred in ≥ 5% of Patients Receiving Lapatinib

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>500 (n = 13)</th>
<th>650 (n = 15)</th>
<th>900 (n = 11)</th>
<th>1,000 (n = 3)</th>
<th>1,200 (n = 12)</th>
<th>1,600 (n = 13)</th>
<th>Total Grade 3 events†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>4</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td>9</td>
<td>28</td>
</tr>
<tr>
<td>Rash</td>
<td>5</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>21</td>
</tr>
<tr>
<td>Nausea</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>7</td>
</tr>
</tbody>
</table>

†Grade 3 adverse events were evaluated using the National Cancer Institute Common Toxicity Criteria version 2.0 (NCI CTC).
No grade 4 drug-related AEs were reported. No additional temporary treatment interruptions, dose-reductions, or withdrawals were associated with drug-related AEs.

Drug-related rash (rash, acne, dermatitis acneiform) was reported in 21 (31%) of 67 patients and was generally mild or moderate (grade 1 or 2) in intensity; only one grade 3 rash was reported (as described in the preceding paragraph). In most patients, the onset of rash occurred between days 2 and 66 and generally resolved without interrupting treatment. Five patients with one or more drug-related skin rash AEs received treatment with dermatologic medications without resolution. The rash remained unresolved at the time of study termination in three patients who did not receive dermatologic medications.

No significant drug-related reductions in LVEF or drug-related occurrences of interstitial pneumonitis were reported; one patient experienced an asymptomatic decrease in LVEF from 37% at baseline to 20% on day 140, which was reported to be related to underlying disease and cor pulmonale rather than lapatinib. The patient, who was granted a protocol exception at screening for LVEF \( \leq 40\% \), continued treatment without interruption until disease progression. The LVEF value returned to near baseline by the time of study termination. Few changes in clinical laboratory values were reported as AEs during the study, and most of these laboratory changes were not related to lapatinib. Three patients had grade 1 anemia at the 500-, 900-, and 1,600-mg dose levels that was considered to be drug-related. Grade 1 anemia resolved on the same day as onset in one patient (900 mg), 5 days after onset in the second patient (500 mg), and remained unresolved in the third patient (1,600 mg). No clinically significant changes in vital sign measurements or ECG results were observed at any dose level, and no patient had ophthalmologic abnormalities.

Only one of 53 serious AEs (grade 2 diarrhea at the 650-mg dose level) was considered to be related to lapatinib. The remainder of the serious AEs were due to hospitalizations for events related to disease progression. There were seven deaths during the study, but none was considered drug-related.

Clinical Activity

Fifty-nine of 67 patients were assessable for disease assessment. Four patients experienced partial responses. All four had breast cancer, overexpressed ErbB2 (3+ by IHC), and with one exception, co-expressed ErbB1. Two of the partial responders had recurrent inflammatory breast cancer, based on clinical history and evidence of dermal-lymphatic invasion on histopathology (Fig 1A). The patients who achieved partial responses (PRs) also had high expression of activated, phosphorylated ErbB2 (p-ErbB2) that was inhibited with lapatinib therapy (Fig 1B and 1C). Detailed analysis of the biologic effects of lapatinib in this study (EGF10004) was described recently. Figure 2 demonstrates the clinical regression observed in one patient with recurrent advanced stage inflammatory breast cancer. All four partial responders were previously treated with trastuzumab, either alone or in combination with multiple chemotherapeutic regimens (eg, anthracycline and/or taxane based). The median duration of treatment for patients with PR was 5.5 months (range, 3 to 8 months). Stable disease (SD) was reported in 24 patients (10 breast cancer, five non–small-cell lung cancer (NSCLC), three colorectal cancer,
three head and neck cancer, one ovarian cancer, one adeno-
carcinoma of unknown primary, and one granular cell carci-
noma). Twenty-two of 28 patients who achieved either PR or
SD received lapatinib treatment for ≥ 3 months, and 12 of
these patients received treatment for ≥ 6 months, including
six patients with breast cancer, two with NSCLC, three with
head and neck cancer, and one with colorectal cancer (Table
3). Four patients received lapatinib treatment for more than
1 year, including a 62-year-old man with colorectal cancer
who received lapatinib for 15 months; a 55-year-old woman
with NSCLC who received lapatinib for 12 months; a 44-year-
old man with head and neck cancer who received lapatinib for
21 months; and a 69-year-old woman with NSCLC who re-
ceived lapatinib for 18 months.

Before discontinuing therapy, the protocol allowed
investigator discretion for intrapatient dose escalation in
patients who were assessed as having progressive disease.
However, there was no instance in which this resulted
in an objective clinical response. At the investigators’ dis-
cretion, doses were increased after 1 to 3 months of treat-
ment in four patients with SD who continued with SD for
an additional 6 to 10 months.

Pharmacokinetics

Median steady-state (day 20) serum concentra-
tion profiles at each dose are shown in Figure 3. Serum con-
centrations peaked on average 3 to 6 hours postdose, and
repeated dosing resulted in an approximately two-fold ac-
cumulation on day 20 relative to day 1 (data not shown).
Steady-state AUC$_{r1}$, C$_{max}$, and C$_{min}$ at each dose are summa-
rized in Table 4. Serum concentrations generally increased
with increasing dose, although variability was high. Concen-
trations at the 1,200-mg dose were a notable exception, re-
sembling those at the 500 mg and 650 mg doses rather than
falling between those at 900 mg and 1,600 mg.

| Table 3. Patients with Partial Responses or Stable Disease Receiving Lapatinib for ≥ 6 Months |
|---|---|---|---|---|
| Dose Level (mg) | Tumor Type | Response* | Duration on Lapatinib (months) |
| 650 | Breast | PR | 8 |
| 1,200 | Breast | PR | 6 |
| 900 | Breast | PR | 6 |
| 1,200 | Head and Neck | SD | 21 |
| 1,600 | NSCLC | SD | 18 |
| 900 | Colorectal | SD | 15 |
| 900 | NSCLC | SD | 12 |
| 500 | Breast | SD | 9.5 |
| 500 | Head and Neck | SD | 9.5 |
| 500 | Breast | SD | 7 |
| 1,200 | Breast | SD | 6 |
| 1,200 | Head and Neck | SD | 6 |

*Response was summarized by the dose to which the patient was
initially assigned. Dose adjustments were permitted; therefore, patients
in the lower dose groups may also have received higher doses of
lapatinib during the course of their treatment.

Abbreviations: PR, partial response; SD, stable disease; NSCLC, non-
small-cell lung cancer.
Dose and Concentration Relationships With Response and Toxicity

The frequency of clinical response, categorized as PR, SD > 6 months, or nonresponders, was examined in relation to drug exposure, in terms of dose, and steady-state AUC, C_{max}, and C_{min}. The relationship with dose (Fig 4) indicates that the majority of responders (PR and SD > 6 months) were receiving 1,200 mg daily (median dose in all responders). The relationship with C_{min} (Fig 5), which demonstrated a right-skewed distribution, indicates that the majority of responders displayed a trough concentration in the 0.3 to 0.6 mg/mL range. The median dose in all patients, as well as responders only, which produced a C_{min} in this range was 900 mg daily. Similar relationships were observed with AUC and C_{max} (data not shown).

Regression analysis suggested that the frequency of diarrhea was linearly related to dose \((P < .03)\) over the 500 to 1,600 mg range. There was no apparent relationship of diarrhea to serum concentration. The incidence of rash showed no apparent relationship to dose or serum concentration, or to clinical response as described for other EGFR inhibitors. Figure 6 shows the incidence of clinical response in relation to lapatinib dose categorized by occurrence of rash. The number of responders (PR and SD > 6 months either alone or combined) was larger without rash compared to those with rash, demonstrating that rash is not an indicator of clinical response to lapatinib.

DISCUSSION

Lapatinib was well tolerated in this study at doses up to 1600 mg daily with clinical activity observed at doses ranging from 650 to 1600 mg daily in heavily pretreated patients with ErbB1-expressing and/or ErbB2-overexpressing metastatic solid tumors. At doses where clinical activity was observed, drug-related toxicity was primarily restricted to grade 1 and 2 diarrhea (42%) and skin rash (31%). No grade 4 toxicity was reported.

Four patients with advanced-stage breast cancer whose disease had progressed on prior trastuzumab and taxane- or anthracycline–based chemotherapy regimens, achieved a PR with lapatinib. All of these patients had tumors that overexpressed ErbB2, and with the one exception, co-expressed ErbB1. In addition, these four patients exhibited baseline expression of activated, phosphorylated ErbB2 that was increased compared with nonresponders (Fig 1). An additional 24 patients experienced disease stabilization. Twelve of 28 patients with either a PR or SD received lapatinib for ≥ 6 months and four patients (NSCLC \([n = 2]\), colorectal, head and neck) received lapatinib therapy for more than 1 year.
Further evidence for the clinical activity of lapatinib in heavily pretreated patients with advanced solid tumors was presented in two studies. Minami et al reported that two patients had PR: one with breast cancer treated with lapatinib 1,600 mg once daily, and the other with squamous cell carcinoma of the lung treated with lapatinib 900 mg once daily. Twelve patients (NSCLC [n = 6], colorectal cancer [n = 3], breast cancer [n = 1], cervical cancer [n = 1], ovarian cancer [n = 1]) had SD, and eight of 14 patients with clinical activity remained on lapatinib therapy for more than 3 months. Versola et al reported a CR in a patient with an ErbB1-overexpressing head and neck squamous cell carcinoma. Twenty-two patients with various tumors, most expressing either ErbB1 or ErbB2, experienced SD with a median duration of 4 months (range 1-13+ months). Together, these studies indicate the potential clinical activity of lapatinib in patients with a variety of solid tumors.

The pharmacokinetics of lapatinib upon repeated dosing display a time-dependent increase in systemic exposure as described previously. For this reason, half-lives and areas under the curve (AUCs) after a single or first dose do not predict accumulation or steady-state concentration, which represents the therapeutically relevant systemic exposure for this chronic therapy. The pharmacokinetics of lapatinib in this study were, on average, similar, but exhibited greater variability than in previous studies of either healthy volunteers or cancer patients. This difference may be secondary to allowing consumption of food with the doses on days 2 through 19 or the effect of concurrent medications required by patients that could alter the absorption and/or metabolism of lapatinib. Absorption of lapatinib is restricted by low solubility and first-pass metabolism by CYP3A4/5, which likely contribute to the variability in systemic exposure. Transporters may also be involved, although lapatinib does not appear to be a substrate for P-glycoprotein (ABCB1).

Clinical responses were generally associated with doses in the middle of the range examined in this study. In terms of either the administered dose or the resulting serum concentration, clinical response was more often associated with doses of 900 to 1,200 mg daily. However, due to the limited response data, it was not possible to adequately characterize the relationship between clinical response and drug exposure. In addition, there was no clear distinction between responders (PR and SD > 6 months) and nonresponders related to drug exposure, suggesting that the distinction between responders and nonresponders may lie in the inherent biologic profile of the tumor, specifically, which signaling pathways are operative, and which pathways are directly involved in regulating tumor cell growth and survival. If tumor cell survival is dependent upon pathways that can be abrogated by lapatinib, then those tumors might be more likely to respond to therapy. If tumors have developed mechanisms to evade apoptosis, and lapatinib exerts its anti-tumor effects through activation of apoptosis, then those tumors might be resistant to lapatinib therapy. Current efforts are focused on identifying a tumor profile that will predict for response to lapatinib therapy.

There has been considerable discussion regarding whether skin rash is requisite to achieve clinical response with ErbB1 inhibitors. In this study, the incidence and severity of skin rash was not associated with clinical response (Fig 5) as reported for other small-molecule ErbB inhibitors (eg, gefitinib, erlotinib). This distinction, along with other differences in biochemical and biologic activity, may relate to the unique 4-anilinoquinazoline structure of lapatinib in contrast to either gefitinib or erlotinib, which are quinazolines.

Lapatanib was well tolerated at doses ranging from 500 to 1,600 mg once daily with grade 1 and 2 diarrhea and rash as the most common drug-related toxicities. The association between diarrhea and dose but not concentration suggests that this toxicity evokes from a local effect on the gut epithelium. Similar and more severe toxicities have been reported in studies of other small-molecule ErbB1 tyrosine kinase inhibitors. In phase I studies of gefitinib and erlotinib,
both reversible inhibitors of ErbB1, the most frequently reported AEs were nausea, vomiting, acneiform rash, and diarrhea in patients treated with gefitinib, and diarrhea, rash, nausea, headache, emesis, and fatigue in patients treated with erlotinib. Dose-limiting toxicities of PKI166, a ErbB1 and ErbB2 tyrosine kinase inhibitor, included grade 3 transaminase elevations, skin rash, and diarrhea. Clinical studies of CI-1033, an irreversible pan-ErbB inhibitor, have shown that the most frequently reported AEs were grade 1 to 2 nausea, emesis, diarrhea, acneiform rash, stomatitis, and asthenia. In addition, reversible dose-limiting hypersensitivity reactions, grade 3 thrombocytopenia, and dose-limiting grade 3 stomatitis have also been reported with CI-1033. 

Treatment with trastuzumab has been reported to be associated with an increased incidence of reversible cardiomyopathy. However, it is not known whether this effect is specific to trastuzumab, or a class effect associated with ErbB2 inhibition. No evidence of drug-related cardiac dysfunction was observed in this study.

Clinical activity was observed at lapatinib daily doses ranging from 500 to 1,600 mg, and most frequently at 900 to 1,200 mg, in heavily pretreated patients with metastatic carcinomas overexpressing ErbB2 and/or expressing ErbB1. Because drug exposure does not appear to distinguish between responders and nonresponders, identification of a tumor profile, based on biologic features, that predicts for response to lapatinib is currently being investigated.

Acknowledgment
We thank the patients who participated in this study and their families. We thank Terry Paul for his assistance in the preparation of the manuscript, and Lini Pandite and Elaine Paul for their critical review of the manuscript. We also thank the staff at the study centers, in particular, Elizabeth Humes, Henry Bell, Roxanne Williams-Truax, Shawna Savage, Noel Willcutt, Sharon Calvert, and Leslie Kosco, for their diligence in identifying and caring for the patients who participated in the study.

Authors’ Disclosures of Potential Conflicts of Interest
Although all authors completed the disclosure declaration, the following authors or their immediate family members indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

### Authors’ Disclosures of Potential Conflicts of Interest

<table>
<thead>
<tr>
<th>Authors</th>
<th>Employment</th>
<th>Leadership</th>
<th>Consultant</th>
<th>Stock</th>
<th>Honoraria</th>
<th>Research Funds</th>
<th>Testimony</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Howard Burris</td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herbert Hurwitz</td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td>Genentech (B)</td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Claire Dees</td>
<td>GlaxoSmithKline (B)</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (B)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kimberly Blackwell</td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthew Ellis</td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beth Overmoyer</td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suzanne Jones</td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jennifer Harris</td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deborah Smith</td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kevin Koch</td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrew Stead</td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steve Mangum</td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neil Spector</td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td>GlaxoSmithKline (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dollar amount codes: (A) $<10,000 (B) $10,000-99,999 (C) $100,000 (N/R) Not Required

### REFERENCES


JOURNAL OF CLINICAL ONCOLOGY


